BAX:NYE-Baxter International Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NYE

Last Closing Price

USD 79.88

Change

+0.64 (+0.81)%

Market Cap

USD 39.08B

Volume

2.79M

Avg Analyst Target

USD 90.13 (+12.83%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Baxter International Inc (BAX) Stock Analysis:
Based on the Baxter International Inc stock forecasts from 9 analysts, the average analyst target price for Baxter International Inc is USD 90.13 over the next 12 months. Baxter International Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Baxter International Inc is Slightly Bearish, which is based on 6 positive signals and 9 negative signals. At the last closing, Baxter International Inc’s stock price was USD 79.88. Baxter International Inc’s stock price has changed by +5.31 % over the past week, +1.84 % over the past month and +2.50 % over the last year.

About

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support th ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BDX Becton Dickinson and Company

+4.22 (+1.71%)

USD69.34B 35.93 16.98
ALC Alcon AG

+3.11 (+3.88%)

USD38.74B 118.45 22.10
RMD ResMed Inc

+5.61 (+2.16%)

USD37.13B 76.29 33.10
WST West Pharmaceutical Services I..

+6.39 (+1.51%)

USD32.16B 52.53 39.43
COO The Cooper Companies Inc

+6.20 (+1.55%)

USD19.31B 6.76 31.91
VAR Varian Medical Systems, Inc

N/A

USD16.26B 58.40 32.91
TFX Teleflex Incorporated

+1.39 (+0.43%)

USD13.93B 33.38 19.71
HRC Hill-Rom Holdings Inc

+0.15 (+0.10%)

USD10.28B 41.87 21.78
NVST Envista Holdings Corporation

+1.47 (+3.68%)

USD6.35B 19.01 15.09
CMD Cantel Medical Corp

N/A

USD3.40B 67.82 19.35

ETFs Containing BAX

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.45% 47% F 33% F
Dividend Return 1.35% 88% B+ 31% F
Total Return 0.90% 47% F 30% F
Trailing 12 Months  
Capital Gain 2.50% 42% F 38% F
Dividend Return 1.39% 88% B+ 26% F
Total Return 3.89% 47% F 34% F
Trailing 5 Years  
Capital Gain 81.22% 36% F 77% C+
Dividend Return 9.60% 86% B 33% F
Total Return 90.81% 36% F 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 10.39% 24% F 61% D-
Dividend Return 1.15% 50% F 27% F
Total Return 11.54% 24% F 58% F
Risk Return Profile  
Volatility (Standard Deviation) 15.05% 81% B- 71% C-
Risk Adjusted Return 76.66% 57% F 80% B-
Market Capitalization 39.08B 94% A 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.35 71% C- 21% F
Price/Book Ratio 4.46 39% F 22% F
Price / Cash Flow Ratio 20.92 47% F 21% F
EV/EBITDA 17.38 77% C+ 31% F
Management Effectiveness  
Return on Equity 14.06% 67% D+ 65% D
Return on Invested Capital 9.74% 72% C- 74% C
Return on Assets 6.21% 84% B 79% C+
Debt to Equity Ratio 66.59% 44% F 53% F
Technical Ratios  
Short Ratio 2.33 78% C+ 47% F
Short Percent 1.21% 72% C- 73% C
Beta 0.61 74% C 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.